Abstract：
Inflammatory bowel diseases (IBDs) are a group of idiopathic, chronic, relapsing, inflammatory conditions, which include ulcerative colitis (UC) and Crohn\'s disease (CD). These disorders are characterised by intestinal symptoms associated with chronic inflammation of the intestinal mucosa, such as gut dysmotility and visceral pain. Currently, the pharmacological management of IBD patients is far from satisfactory in terms of efficacy and safety, thus spurring the interest of the scientific community to identify novel molecular targets for the management of these disorders. According to recent research, it appears that P2 purinergic receptors, which can regulate the host\'s response to inflammation, have been identified as potential targets for the treatment of IBDs. In particular, among P2 receptors, the P2X4 receptor subtype has recently captured the attention of the research community owing to its role in shaping immune/inflammatory responses. Based on this evidence, the present review has been conceived to provide a critical appraisal of the available knowledge about the role of P2X4R subtype in the pathophysiological mechanisms underlying IBDs, pointing out its potential as therapeutic target to develop innovative therapeutic strategies aimed at counteracting the inflammatory process, gut dysmotility and visceral hypersensitivity associated with these disorders.
摘要：
炎症性肠病(IBDs)是一组特发性,慢性，复发，炎症条件，其中包括溃疡性结肠炎（UC）和克罗恩病（CD）。这些疾病的特征是与肠粘膜慢性炎症相关的肠道症状，如肠道运动障碍和内脏疼痛。目前,IBD患者的药物治疗在疗效和安全性方面远不能令人满意，从而激发了科学界的兴趣，以确定新的分子靶标来管理这些疾病。根据最近的研究,看来P2嘌呤能受体，可以调节宿主对炎症的反应，已被确定为IBD治疗的潜在目标。特别是,在P2受体中，P2X4受体亚型由于其在形成免疫/炎症反应中的作用,最近引起了研究界的关注.根据这些证据,本综述旨在对有关P2X4R亚型在IBDs病理生理机制中的作用的现有知识进行批判性评估，指出其作为治疗目标的潜力，以开发旨在抵消炎症过程的创新治疗策略，与这些疾病相关的肠道运动障碍和内脏超敏反应。
